目的 探討鼠神經(jīng)生長因子聯(lián)合神經(jīng)節(jié)苷脂對早產(chǎn)兒腦神經(jīng)功能的調(diào)節(jié)作用。方法 選擇2017年6月—2019年6月商洛市中心醫(yī)院收治的早產(chǎn)兒86例，隨機分為兩組，每組各43例。對照組靜脈滴注單唾液酸四己糖神經(jīng)節(jié)苷脂鈉注射液，將20 mg藥物混入10%葡萄糖注射液20 mL中靜脈滴注，對于病情嚴(yán)重的患兒可增加1～2個療程。觀察組在對照組治療的基礎(chǔ)上聯(lián)合使用注射用鼠神經(jīng)生長因子，每瓶用2 mL氯化鈉注射液溶解后肌肉注射，1次/d。兩組患兒連續(xù)治療10 d為1個療程，共治療3個療程。觀察兩組患者的臨床療效，比較兩組患兒的臨床癥狀恢復(fù)時間、神經(jīng)損傷標(biāo)志物水平和NBNA評分。結(jié)果 治療后，觀察組新生兒臨床治療總有效率為90.70%，明顯高于對照組的69.77%（P<0.05）。治療后，觀察組新生兒意識恢復(fù)時間、吮吸能力恢復(fù)時間、原始反射恢復(fù)時間和肌張力恢復(fù)時間均明顯少于對照組（P<0.05）。治療后，兩組新生兒血清髓鞘堿性蛋白（MBP）、S-100β蛋白水平均明顯降低（P<0.05），觀察組降低程度更為顯著（P<0.05）。治療后，兩組早產(chǎn)兒NBNA評分逐漸升高且高于治療前（P<0.05），觀察組改善程度優(yōu)于對照組（P<0.05）。結(jié)論 鼠神經(jīng)生長因子聯(lián)合神經(jīng)節(jié)苷脂治療早產(chǎn)兒后能夠明顯降低早產(chǎn)兒神經(jīng)損傷標(biāo)志物MBP、S-100β水平，縮短神經(jīng)功能恢復(fù)時間，提高NBNA評分，提高臨床治療效果，可推廣使用。

Objective To investigate the regulation of mouse nerve growth factor combined with gangliosides on the neurological function of premature infants. Methods A total of 86 cases of premature infants admitted to Shangluo Central Hospital from June 2017 to June 2019 were randomly divided into two groups, each group had 43 cases. Patients in the control group were given intravenous infusion of Monosialotetrahexosylganglioside Sodium Injection, 20 mg added into 10% glucose injection 20 mL, which could add 1 to 2 courses of treatment for severely ill children. Patients in the observaton group were given intravenous infusion of Mouse Nerve Growth Factor for Injection on the basis of control group, and each bottle was dissolved with 2 mL sodium chloride injection and intramuscular injection, once daily. Two groups of children were treated for 10 consecutive days for one course of treatment, a total of three courses of treatment. After treatment, the clinical efficacy was evaluated, and the clinical symptom recovery time, nerve injury marker level, and NBNA score in two groups were compared. Results After treatment, the total effective rate of neonatal clinical treatment in the observation group was 90.70%, which was significantly higher than 69.77% in the control group (P<0.05). After treatment, the recovery time of neonatal consciousness, sucking ability, original reflex, and the recovery time of muscle tension in the observation group were significantly less than those in the control group (P<0.05). After treatment, the levels of MBP and S-100β protein in two groups were significantly decreased (P<0.05), and and the decrease was more significant in the observation group (P<0.05). After treatment, NBNA score of premature infants in two groups were increased gradually and it was higher than that before treatment (P<0.05), and the improvement degree in the observation group was better than that in the control group (P<0.05). Conclusion Mouse nerve growth factor combined with ganglioside can significantly reduce the levels of nerve injury markers MBP and S-100β in premature infants, shorten the recovery time of neurological function, improve the NBNA score, and improve the clinical therapeutic effect, which can be widely used.

陜西省衛(wèi)生健康科研基金項目（2018C006）